埃尔特罗姆博帕格
医学
卡铂
安慰剂
临床终点
内科学
恶心
不利影响
胃肠病学
化疗
血小板生成素受体
随机对照试验
外科
血小板
血小板生成素
顺铂
病理
免疫性血小板减少症
替代医学
造血
生物
遗传学
干细胞
作者
A. Kellum,Agnieszka Jagiełło-Gruszfeld,Igor Bondarenko,Rita Patwardhan,C. Messam,Yasser Mostafa Kamel
标识
DOI:10.1185/03007995.2010.510051
摘要
Objectives:Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, has been shown to increase platelet counts in adults with chronic immune thrombocytopenia and chronic hepatitis C. This multicenter phase 2 study assessed the efficacy and safety of eltrombopag in patients receiving first-line carboplatin/paclitaxel for the treatment of advanced solid tumors.Research design and methods:Patients (N = 183) were randomized to placebo or eltrombopag 50 mg, 75 mg, or 100 mg given orally following chemotherapy on days 2 through 11 of each 21-day cycle, for at least two cycles. The primary endpoint was the difference in platelet count from day 1 in cycle 2 to the platelet nadir in cycle 2.Clinical trial registry number:NCT00102726.Results:Although the primary endpoint was not met, postnadir platelet counts increased during cycles 1 and 2 in all eltrombopag treatment groups compared with placebo. The most commonly reported adverse events across all study arms (including placebo) were nausea and alopecia and eltrombopag was generally well tolerated.Conclusions:This study provides preliminary information that eltrombopag does increase platelets in patients receiving chemotherapy for advanced solid tumors. Further investigation is needed to identify the optimal dose(s) and schedule of eltrombopag in patients receiving myelosuppressive chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI